Neuropathix, Inc. (NPTX)
Neuropathix, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Doylestown, PA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $28,143. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -2176.0%. Its beta of 1.65 implies it has historically moved more than the broad market.
Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying, advancing, and bringing to market innovative treatments derived from its exclusive platform of synthetic cannabinoid derivatives. The company's efforts are concentrated on the research and preclinical development of chemical compounds like KLS-13019, KLS-13023, and KLS-13022, alongside associated molecules and synthetic cannabidiol-based therapies. These investigational drugs are being explored for their potential application in treating various conditions, including chemotherapy-induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. Previously operating as Kannalife, Inc., the organization rebranded as Neuropathix, Inc. in November 2020. Established in 2010, Neuropathix, Inc. maintains its headquarters in Doylestown, Pennsylvania.
Neuropathix, Inc. is most often compared with the following Healthcare names: